A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 Studies

Abstract Introduction Clinicians, payers, guideline committees, and policymakers support the use of high-intensity statins in patients at high risk for complications of cardiovascular disease (CVD). Guidelines and recommendations provide guidance on next steps for patients with inadequate low-densit...

Description complète

Détails bibliographiques

Auteurs principaux:	Michael J. Koren, Peter H. Jones, Jennifer G. Robinson, David Sullivan, Leslie Cho, Thomas Hucko, J. Antonio G. Lopez, Alex N. Fleishman, Ransi Somaratne, Erik Stroes
Format:	Artigo
Langue:	Inglês
Publié:	Adis, Springer Healthcare 2020-06-01
Collection:	Cardiology and Therapy
Sujets:	Dyslipidemia Evolocumab Ezetimibe Lipid-lowering therapy PCSK9 inhibition
Accès en ligne:	https://doi.org/10.1007/s40119-020-00181-8
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!